Matches in Wikidata for { <http://www.wikidata.org/entity/Q90046887> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- Q90046887 description "artículu científicu espublizáu n'abril de 2019" @default.
- Q90046887 description "bài báo khoa học" @default.
- Q90046887 description "scientific article published on 01 April 2019" @default.
- Q90046887 description "wetenschappelijk artikel" @default.
- Q90046887 description "наукова стаття, опублікована 1 квітня 2019" @default.
- Q90046887 name "Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind," @default.
- Q90046887 name "Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind," @default.
- Q90046887 type Item @default.
- Q90046887 label "Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind," @default.
- Q90046887 label "Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind," @default.
- Q90046887 prefLabel "Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind," @default.
- Q90046887 prefLabel "Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind," @default.
- Q90046887 P1433 Q90046887-86EDFB12-3A85-4860-88FF-D87920550385 @default.
- Q90046887 P1476 Q90046887-BDEE2CD7-D445-4905-8176-A15877E67139 @default.
- Q90046887 P2093 Q90046887-00E5E944-E162-42EC-8B7E-256AB9BF7A0A @default.
- Q90046887 P2093 Q90046887-14E05072-158F-4712-A7AA-8F627451199B @default.
- Q90046887 P2093 Q90046887-3882D847-2C3D-40D5-97E5-0EE273AF3A9E @default.
- Q90046887 P2093 Q90046887-4B6A3276-E46B-4CBC-BC34-6A8063A9990A @default.
- Q90046887 P2093 Q90046887-5B1AC026-72A9-4F36-9014-E82C3659BB9A @default.
- Q90046887 P2093 Q90046887-6364D585-65E6-4B34-A453-E1721EA71293 @default.
- Q90046887 P2093 Q90046887-6A6E99EA-4D3B-4CB9-ABCB-04D64CD6429D @default.
- Q90046887 P2093 Q90046887-6A79D78F-B8EE-4770-888F-DA61608FB465 @default.
- Q90046887 P2093 Q90046887-6DC3D2D4-E24E-4C91-A123-91EED10BD16E @default.
- Q90046887 P2093 Q90046887-9D0DD88B-710E-4A03-A887-B6E682F932AE @default.
- Q90046887 P2093 Q90046887-B71E80D6-645B-4F69-9B9E-AD2E188A21FA @default.
- Q90046887 P2093 Q90046887-BDABFCE0-0CB0-411E-BACB-EB79300D4D0C @default.
- Q90046887 P2093 Q90046887-BE9F59BD-B640-40D2-BBDC-A23833051544 @default.
- Q90046887 P2093 Q90046887-D0E42BD1-DD48-42F7-B153-590ABD57DAD0 @default.
- Q90046887 P2093 Q90046887-D58D0AB7-4B2E-4C97-B46E-E5DCCA927145 @default.
- Q90046887 P2093 Q90046887-DD269538-914A-493C-889A-1126044FA054 @default.
- Q90046887 P2093 Q90046887-F65D0731-0788-4806-B24B-EE8377295FD6 @default.
- Q90046887 P304 Q90046887-2BF8BC72-55F2-4E36-BF4F-131214E9EE1D @default.
- Q90046887 P31 Q90046887-576452BF-3B5B-4984-BB82-2A862268AABE @default.
- Q90046887 P356 Q90046887-F5A692C1-8B27-44C2-BDF9-C0692DC04B78 @default.
- Q90046887 P478 Q90046887-A43223D0-2A63-4AB3-A158-2EF870745CD2 @default.
- Q90046887 P577 Q90046887-E5595FE2-0101-4234-AEC6-125628A13320 @default.
- Q90046887 P921 Q90046887-C3746E7C-4512-4099-9377-8C68EF457247 @default.
- Q90046887 P356 MDZ094 @default.
- Q90046887 P1433 Q326122 @default.
- Q90046887 P1476 "Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study" @default.
- Q90046887 P2093 "A Navarro" @default.
- Q90046887 P2093 "C Baudelet" @default.
- Q90046887 P2093 "D Morgensztern" @default.
- Q90046887 P2093 "H R Kim" @default.
- Q90046887 P2093 "I Percent" @default.
- Q90046887 P2093 "J Fairchild" @default.
- Q90046887 P2093 "J Rodriguez-Cid" @default.
- Q90046887 P2093 "J S Lee" @default.
- Q90046887 P2093 "K Park" @default.
- Q90046887 P2093 "M Reck" @default.
- Q90046887 P2093 "M Schenker" @default.
- Q90046887 P2093 "N Ready" @default.
- Q90046887 P2093 "R Govindan" @default.
- Q90046887 P2093 "S Peters" @default.
- Q90046887 P2093 "S R Dakhil" @default.
- Q90046887 P2093 "T K Owonikoko" @default.
- Q90046887 P2093 "V Gutierrez" @default.
- Q90046887 P304 "ii77" @default.
- Q90046887 P31 Q13442814 @default.
- Q90046887 P356 "10.1093/ANNONC/MDZ094" @default.
- Q90046887 P478 "30 Suppl 2" @default.
- Q90046887 P577 "2019-04-01T00:00:00Z" @default.
- Q90046887 P921 Q269829 @default.